Publications by authors named "Andrew H Wei"

52Publications

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

N Engl J Med 2020 08;383(7):617-629

From the Department of Leukemia, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., M.K.); the Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento (B.A.J.), the Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte (V. Pullarkat), and Genentech, South San Francisco (W.-J.H.) - all in California; the Section of Hematology and Oncology, Department of Medicine, University of Chicago Medicine, Chicago (M.J.T.), and AbbVie, North Chicago (Y.Z., J.P.) - both in Illinois; the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston (J.S.G., A.L.); the Australian Centre for Blood Diseases, Alfred Hospital and Monash University, Melbourne, VIC (A.H.W.); the Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany (H.D.); Hôpital St. Louis, Assistance Publique-Hôpitaux de Paris and Université de Paris, Paris (P.F.); the Third Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna (E.K.); the Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels (V.H.); the Department of Medicine, McMaster University, Hamilton, ON, Canada (B.L.); the Department of Hematology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, Barcelona (J.E.); the Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China (J.W.); the Department of Hematology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia (V. Pejsa); the Department of Clinic Subjects, University Hospital Ostrava-Poruba, Ostrava, Czech Republic (R.H.); Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki (K.P.); the Faculty of Medicine, Department of Hematology, University of Debrecen, Debrecen, Hungary (A.I.); Hadassah Medical Center, Jerusalem (D.L.); the Clinic of Hematology, Department of Internal Medicine, University of Genoa, and San Martino Hospital IRCCS - both in Genoa, Italy (R.M.L.); the Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan (K.Y.); the Department of Internal Medicine, Seoul National University College of Medicine (S.-S.Y.), and the Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine (J.-H.J.) - both in Seoul, South Korea; the Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan (S.-P.Y.); the Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Ondokuz Mayıs University, Samsun, Turkey (M.T.); and Abramson Cancer Center, University of Pennsylvania, Philadelphia (K.W.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2012971DOI Listing
August 2020

Androgens stimulate erythropoiesis through the DNA-binding activity of the androgen receptor in non-hematopoietic cells.

Eur J Haematol 2020 Sep 15;105(3):247-254. Epub 2020 May 15.

Central Clinical School, Australian Centre for Blood Diseases, Monash University, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13431DOI Listing
September 2020

How I treat acute myeloid leukemia in the era of new drugs.

Blood 2020 01;135(2):85-96

Department of Haematology, The Alfred Hospital and Monash University, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019001239DOI Listing
January 2020

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?

Cancer Discov 2019 Aug;9(8):998-1000

Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-0575DOI Listing
August 2019

Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia.

J Clin Oncol 2019 07 21;37(21):1785-1789. Epub 2019 May 21.

2 Alfred Hospital, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/JCO.19.00400
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00400DOI Listing
July 2019

Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome.

Best Pract Res Clin Haematol 2019 03 27;32(1):3-12. Epub 2019 Feb 27.

The Alfred Hospital and Monash University, Melbourne, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2019.02.007DOI Listing
March 2019

Maintenance therapy for AML: are we there yet?

Authors:
Andrew H Wei

Blood 2019 03;133(13):1390-1392

The Alfred Hospital; Monash University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2019-02-897579DOI Listing
March 2019

New drugs creating new challenges in acute myeloid leukemia.

Genes Chromosomes Cancer 2019 12 11;58(12):903-914. Epub 2019 Apr 11.

Department of Haematology, The Alfred Hospital and Monash University, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22750DOI Listing
December 2019

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

Cancer Cell 2018 12;34(6):879-891

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183052
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.11.004DOI Listing
December 2018

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.

Blood 2017 12 19;130(23):2469-2474. Epub 2017 Oct 19.

Department of Clinical Haematology, Alfred Hospital, Melbourne, Australia; and.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2017-08
Publisher Site
http://dx.doi.org/10.1182/blood-2017-08-784066DOI Listing
December 2017

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

J Clin Oncol 2017 May 3;35(15):1678-1685. Epub 2017 Apr 3.

Kenneth F. Bradstock and Warwick Benson, Westmead Hospital, University of Sydney; Arno Enno, Sandra Deveridge, and Philip Rowlings, Calvary Mater Newcastle Hospital, Newcastle; Luke Coyle, Royal North Shore Hospital, St Leonards; Campbell Tiley, Central Coast Health, Gosford; John Moore, St Vincent's Hospital; Mark Hertzberg, Prince of Wales Hospital, Sydney; Kimberly Cartwright, Wollongong Hospital, Wollongong; Ilona Cunningham, Concord Repatriation General Hospital, Concord; John Taper, Nepean Hospital, Penrith, New South Wales; Emma Link, Juliana Di Iulio, and John F. Seymour, Peter MacCallum Cancer Centre; Jeff Szer, Andrew Grigg, Andrew W. Roberts, and John F. Seymour, University of Melbourne; Andrew H. Wei, Monash University; Anthony Schwarer, Box Hill Hospital; Lynda Campbell, Victorian Cancer Cytogenetics Service, Melbourne; Jeff Szer, Andrew Grigg, and Andrew W. Roberts, Royal Melbourne Hospital, Parkville; Phillip Campbell, Deakin University School of Medicine, Geelong, Victoria; Paula Marlton, Anthony K. Mills, and Devinder Gill, University of Queensland, Brisbane, Queensland; Ray M. Lowenthal, University of Tasmania, Hobart, Tasmania; Ian D. Lewis and Peter Bardy, Royal Adelaide Hospital; Uwe Hahn, Queen Elizabeth Hospital, Adelaide, South Australia; James D'Rozario, The Canberra Hospital, Garran, Canberra, Australia Capital Territory; Gavin Cull, Sir Charles Gairdner Hospital; Michael F. Leahy, University of Western Australia; and Paul Cannell, Royal Perth Hospital, Perth, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.6374
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.6374DOI Listing
May 2017

'Did He Who Made the Lamb Make Thee?' New Developments in Treating the 'Fearful Symmetry' of Acute Myeloid Leukemia.

Trends Mol Med 2017 03 11;23(3):264-281. Epub 2017 Feb 11.

The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Department of Medical Biology, University of Melbourne, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2017.01.005DOI Listing
March 2017

Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia.

Br J Haematol 2017 04 31;177(2):328-330. Epub 2016 Mar 31.

Department of Haematology, Alfred Hospital, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14063DOI Listing
April 2017

Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.

Bioorg Med Chem 2015 Oct 28;23(19):6280-96. Epub 2015 Aug 28.

ACRF Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, 1G Royal Parade, VIC 3052, Australia; School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, 30 Flemington Rd, VIC 3010, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2015.08.035DOI Listing
October 2015

Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML.

Blood 2015 Apr 3;125(18):2815-24. Epub 2015 Mar 3.

Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia; Department of Clinical Haematology, The Alfred Hospital, Melbourne, VIC, Australia;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-09-603555DOI Listing
April 2015

The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.

Pathology 2011 Oct;43(6):536-46

Department of Clinical Haematology, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAT.0b013e32834a4061DOI Listing
October 2011

Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1.

PLoS Pathog 2010 Dec 23;6(12):e1001236. Epub 2010 Dec 23.

The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.ppat.1001236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3009601PMC
December 2010

New insights into the haemostatic function of platelets.

Br J Haematol 2009 Nov 28;147(4):415-30. Epub 2009 Jul 28.

The Australian Centre for Blood Diseases, Monash University, Department of Haematology, Alfred Hospital, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.07819.xDOI Listing
November 2009

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.

Proc Natl Acad Sci U S A 2008 Nov 11;105(46):17961-6. Epub 2008 Nov 11.

The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3050, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0809957105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582212PMC
November 2008

Bortezomib: putting mantle cell lymphoma on death row.

Leuk Lymphoma 2008 Apr;49(4):657-8

Department of Malignant Haematology and Stem Cell Transplantion, The Alfred Hospital, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190801942378DOI Listing
April 2008